TICKERNERD
Menu
IRTCIRTCHealthcare · Medical Devices

IRTC Stock Forecast: iRhythm Holdings, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$109
−2.17% on the day

The 15 Wall Street analysts covering iRhythm Holdings, Inc. hold a median 12-month price target of $178 — +62.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 19 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$3.6B
Ticker Nerd rank
74 / 100
Median analyst target
$178
Analysts covering
15
Revenue$224.2M+20.1% y/y
Operating income$11.4M
Net income−$381K
Free cash flow$37.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.9%
1M
−5.1%
YTD
−38.4%
1Y
−38.0%
From 52W high
−42.2%
From 52W low
+7.4%
$102
$189
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IRTC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores iRhythm Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
74 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
91
Growth
89
Accruals
70
Issuance
65
Revisions
63
Volatility
63
Value
58
Size
28
Momentum
21

Quality (91): The business earns solid, repeatable profits on what it owns.

Momentum (21): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IRTC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IRTC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$120$140$160$180$200Oct 25Jan 26Apr 26Jul 26IRTCHigh $196Median $178Low $157

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
15 Buy0 Hold0 Sell
Low $157Median $178High $196

The green dot is the last close — the median target sits +62.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
18 Aug 2026Wells FargoMaintainsOverweight$180 → $168
10 Aug 2026Truist SecuritiesMaintainsBuy$160 → $168
10 Aug 2026Truist SecuritiesMaintainsBuy—
7 Aug 2026Evercore ISI GroupMaintainsOutperform—
7 Aug 2026Evercore ISI GroupMaintainsOutperform$150 → $165
7 Aug 2026NeedhamMaintainsBuy$255 → $192
7 Aug 2026NeedhamMaintainsBuy—
7 Aug 2026Wells FargoMaintainsOverweight—
7 Aug 2026Wells FargoMaintainsOverweight$180 → $168
23 July 2026Stephens & Co.InitiatesOverweight$160
23 July 2026Stephens & Co.InitiatesOverweight—
16 July 2026Truist SecuritiesMaintainsBuy$174 → $160
16 July 2026Truist SecuritiesMaintainsBuy—
6 July 2026Evercore ISI GroupMaintainsOutperform—
22 June 2026BTIGReiteratesBuy—
10 June 2026BTIGReiteratesBuy—
1 June 2026Canaccord GenuityMaintainsBuy—
18 May 2026B of A SecuritiesMaintainsBuy—
4 May 2026CitigroupMaintainsBuy—
1 May 2026Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IRTC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IRTC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, iRhythm Holdings, Inc. returned −38.0% against +16.3% for the S&P 500, dividends included.

IRTC vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Oct 25Jan 26Apr 26Jul 26IRTCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IRTC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+400.7%
Analysts raising
9
Analysts cutting
0
Fundamentals

iRhythm Holdings, Inc. (IRTC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−78.7×

Cheaper than 99% of US stocks

Price / sales
4.4×

Cheaper than 28% of US stocks

Price / book
19.4×

Cheaper than 5% of US stocks

EV / EBITDA
211.4×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
20.1%

Higher than 69% of US stocks

Earnings growth (YoY)
20.1%

Higher than 58% of US stocks

Gross margin
72.8%

Higher than 85% of US stocks

Operating margin
7.9%

Higher than 60% of US stocks

Net margin
−1.7%

Higher than 28% of US stocks

Returns & dividend
Return on equity
−9.6%

Higher than 36% of US stocks

Return on assets
0.6%

Higher than 47% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

iRhythm Holdings, Inc. (IRTC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • iRhythm Holdings, Inc. has a market value of $3.6B and an enterprise value of $3.7B.

  • Revenue in the twelve months to 30 June 2026: $825.3M. The latest quarter grew 20.1% year on year.

  • Net income over the same four quarters: −$13.9M, a −1.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.43.

  • Free cash flow in the twelve months to 30 June 2026: $39.0M.

  • Shares outstanding: 32.9M.

  • Trailing P/E: −78.7×; forward P/E: 90.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • iRhythm Holdings, Inc. employs 2,400 people — $344K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

IRTC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
IRTCiRhythm Holdings, Inc.$3.6B
74
LIVNLivaNova PLC$4.3B
97
TMDXTransMedics Group, Inc.$3.0B
29
ITGRInteger Holdings Corp.$4.4B
74
NEOGNeogen Corp.$2.8B
97
AXGNAxoGen, Inc.$2.6B
79
HAEHaemonetics Corp.$5.1B
99

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own iRhythm Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IRTC news & analysis

Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated?

Zacks Investment Research · 4 Sept 2026neutral

iRhythm reported stronger Q2 performance, including revenue growth, margin expansion and record free cash flow. However, the company continues to face elevated reimbursement and regulatory risks.

Why it matters — An IRTC watcher would care because the improved financial results strengthen the company's case while persistent reimbursement and regulatory uncertainties remain key risks to monitor.

iRhythm Holdings to Participate in Wells Fargo 21st Annual Healthcare Conference

GlobeNewsWire · 26 Aug 2026neutral

iRhythm Holdings, Inc. announced that it will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference, as stated in a press release dated August 26, 2026. No additional details about the conference appearance were provided.

Why it matters — The company's participation in a major healthcare conference gives investors and industry watchers an opportunity for iRhythm's leadership to share updates and engage with the broader sector audience.

iRhythm: The Algorithmic Margin Inflection Changes The Story

Seeking Alpha · 21 Aug 2026positive

iRhythm reported a Q2 2026 financial inflection with 20.1% revenue growth, gross margin expanding to 72.8%, and adjusted EBITDA margin reaching 19.3%, alongside raised full-year guidance and record free cash flow. The company is evolving from a cardiac patch producer into a comprehensive cardiac monitoring platform, with its ZEUS platform's FDA clearance expected to cut clinician review time by 50% and target $100 million in cost savings over five years.

Why it matters — IRTC watchers would care because the quarter marks a shift from its hardware-based model to a higher-margin software and workflow platform, with margin expansion and raised guidance signalling a potential change in the company's financial narrative.

Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

PRNewsWire · 17 Aug 2026negative

A law firm is investigating whether insiders at iRhythm Technologies, Inc. breached their fiduciary duties to shareholders. The firm is encouraging shareholders to contact them at no cost about their legal rights and options.

Why it matters — IRTC watchers would care because the notice points to a potential shareholder investigation or legal action concerning insider conduct at the company.

iRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform

Zacks Investment Research · 14 Aug 2026positive

iRhythm Holdings announced plans to acquire VitalConnect, a move that expands its cardiac monitoring platform across ambulatory, inpatient and hospital-to-home care settings. According to the report, the deal opens new growth opportunities for the company.

Why it matters — The acquisition broadens iRhythm's cardiac monitoring capabilities into additional care settings, potentially widening its market reach for investors tracking the company.

FAQ

Frequently asked questions about IRTC stock

What is the IRTC stock price forecast for 2026-2027?

The 15 Wall Street analysts covering iRhythm Holdings, Inc. have a median 12-month price target of $178, with estimates ranging from $157 to $196. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IRTC stock a buy right now?

Of the 15 analysts covering iRhythm Holdings, Inc., 15 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks iRhythm Holdings, Inc. 74 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IRTC?

As at 19 Sept 2026, iRhythm Holdings, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (91 of 100).

Will IRTC stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +62.4% from the last close, and Ticker Nerd's factor model ranks iRhythm Holdings, Inc. 74 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IRTC stock forecast for 2030?

No analyst covering iRhythm Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRTC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $157 to $196 over the next 12 months.

How has IRTC stock performed over the past year?

iRhythm Holdings, Inc. returned -38.0% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does iRhythm Holdings, Inc. do?

iRhythm Holdings, Inc. is a digital healthcare company focused on ambulatory cardiac monitoring and arrhythmia detection.

What is the latest news on IRTC?

The most recent item we track (Zacks Investment Research, 4 Sept 2026): "Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated?". iRhythm reported stronger Q2 performance, including revenue growth, margin expansion and record free cash flow. However, the company continues to face elevated reimbursement and regulatory risks.

Company

About iRhythm Holdings, Inc.

iRhythm Holdings, Inc. is a digital healthcare company focused on ambulatory cardiac monitoring and arrhythmia detection. The company develops and commercializes wearable, device-based technology that helps clinicians capture and analyze heart rhythm data outside of the hospital setting. Its product portfolio includes remote ECG monitoring systems and connected software tools that support physician review, patient data collection, and clinical workflow management. iRhythm Holdings serves cardiology, electrophysiology, primary care, and other specialty practices that rely on timely rhythm assessment to guide diagnosis. The company’s platform combines biosensors, cloud-based analytics, and proprietary algorithms to turn long-duration heartbeat data into clinically useful reports. Headquartered in San Francisco, iRhythm Holdings operates in the healthcare technology and medical devices market, where it plays a specialized role in noninvasive cardiac diagnostics.

CEO Mr. Quentin S. Blackford · 2,400 employees · United States · https://www.irhythmtech.com